The HSP90AB1 Knockout CAL-27 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal cell population derived from the CAL-27 human oral squamous cell carcinoma line, featuring targeted disruption of the HSP90AB1 gene. This polyclonal knockout model introduces loss-of-function mutations across a heterogeneous cell pool, enabling functional studies of HSP90AB1-dependent chaperone activity in an epithelial tumor context. The product is supplied as a viable, ready-to-culture cell population without clonal selection.
CAL-27 is a well-characterized cell line established from a human tongue squamous cell carcinoma, representing an adherent epithelial tumor model with robust in vitro growth. It retains key features of oral squamous cell carcinoma, including dysregulated signaling through oncogenic PI3K/AKT and MAPK/ERK pathways, and is widely used to study tumor cell proliferation, migration, and drug response in head and neck cancer.
HSP90AB1 encodes the beta isoform of the 90-kDa heat shock protein, an ATP-dependent molecular chaperone that governs the folding, stability, and activity of numerous client proteins, including kinases and steroid hormone receptors. It stabilizes critical oncogenic drivers such as EGFR, HER2, AKT, CDK4, and HIF-1??, and is activated by heat shock, growth factors, oncogenic stress, and hypoxia. The chaperone cooperates with co-chaperones CDC37, AHA1, p23, and HSP70. Knockout of HSP90AB1 disrupts these complexes, leading to proteasomal degradation of clients and attenuation of RAS?CRAF?CMEK?CERK and PI3K?CAKT?CmTOR pathways, as well as NF-??B signaling and cell cycle regulation.
In CAL-27 cells with activated EGFR and PI3K/AKT signaling, loss of HSP90AB1 impairs client protein stability and tumor cell fitness. The polyclonal population allows interrogation of chaperone dependency in a polygenic cancer background, avoiding pharmacological off-target effects. This model enables studies of apoptosis, cell cycle arrest, and invasion, and can reveal synthetic lethal interactions or adaptive resistance mechanisms upon HSP90 loss.
This knockout model supports western blotting for client degradation (e.g., EGFR, AKT, survivin), MTT viability assays, annexin V apoptosis detection, and transwell migration/invasion assays. Co-immunoprecipitation probes client?Cchaperone interactions, RT-qPCR validates gene disruption, and HSP90 inhibitor testing (e.g., geldanamycin) allows comparison of genetic ablation versus pharmacological inhibition. Contact Ascent Research for further details.
